| |
|
PDF
POSTER
Racial Differences in
Response to EFV-Containing vs. LPV/r-Containing Regimens
JL Guest , QS Ataher , D Rimland, et al
 PDF Poster
|
PDF POSTER
48-Week Final Results of Lopinavir/r
(LPV/r)-Efavirenz (EFV) Combination (BIKS Study)
F Raffi, C Allavena, JF Delfraissy, et al;
44th ICAAC
PDF Poster
300-Week Follow-Up Lopinavir/Ritonavir (LPV/r)-Based Therapy in
Antiretroviral (ARV)-Naive,
HIV-Infected Patients
C. Benson, B. Ds Silva , F. McMillan, et al
Abstract
Inter-Individual and Intra-Patient Variabilities in Lopinavir
and Ritonavir Trough Plasma
Concentrations in HIV-Infected Patients Warrant Therapeutic Drug
Monitoring
J. Poirier , O. Zoual, J. Girard, et al
Abstract
|
Stability of Lopinavir/ritonavir (LPV/RTV) at Elevated
Temperatures: Relevance to HIV Therapy
in Sub-Saharan Africa
E. Capparelli, A Pau, D. Holland, et al
Abstract
|
Incidence of Plasma Lipids Changes and Correlation with
Lopinavir/r Concentrations in HIV
Infected Patients: a 24-Week, Prospective Multicenter Study
J. Meynard, K. Lacombe, J. Poitier, et al
Abstract
|
A Comparison of Resting Energy, Substrate Oxidation Rates and
Endogenous Glucose
Production in HIV-Negative Subjects after Short-Term Treatment
with Atazanavir (ATV) or
Lopinavir/ritonavir (LPV/r)
MA. Noor, J. Maa , RA. Parker. et al
Abstract
|
|
|
|
|
Main
New/Newsworthy